<div id="readability-page-1"><p>Roffman Miller Associates Inc. PA cut its holdings in  Albemarle Corporation (NYSE:ALB - Free Report) by 25.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,367 shares of the specialty chemicals company's stock after selling 7,650 shares during the quarter. Roffman Miller Associates Inc. PA's holdings in Albemarle were worth $1,814,000 as of its most recent SEC filing.</p><ul><li>3 Signals Pointing to a Turnaround for Albemarle</li></ul><p>A number of other large investors also recently bought and sold shares of the business. Hantz Financial Services Inc. raised its position in shares of  Albemarle by 10,050.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 406 shares of the specialty chemicals company's stock worth $25,000 after acquiring an additional 402 shares in the last quarter.  CVA Family Office LLC increased its holdings in shares of  Albemarle by 7,257.1% during the second quarter. CVA Family Office LLC now owns 515 shares of the specialty chemicals company's stock valued at $32,000 after acquiring an additional 508 shares in the last quarter.  EverSource Wealth Advisors LLC raised its position in shares of  Albemarle by 536.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 573 shares of the specialty chemicals company's stock valued at $36,000 after purchasing an additional 483 shares during the last quarter.  Assetmark Inc. boosted its stake in  Albemarle by 248.0% in the 2nd quarter. Assetmark Inc. now owns 689 shares of the specialty chemicals company's stock worth $43,000 after purchasing an additional 491 shares in the last quarter.  Finally, ST Germain D J Co. Inc. purchased a new stake in  Albemarle during the 2nd quarter worth approximately $47,000. Institutional investors own  92.87% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>A number of research firms have issued reports on ALB. Royal Bank Of Canada  reaffirmed an &#34;outperform&#34; rating and issued a $159.00 price target on shares of Albemarle in a report on Thursday. Cowen  restated a &#34;hold&#34; rating on shares of Albemarle in a research note on Thursday, October 9th. UBS Group raised Albemarle from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their price target for the stock from $107.00 to $185.00 in a research report on Friday, December 5th. Morgan Stanley  reissued an &#34;equal weight&#34; rating on shares of Albemarle in a report on Friday. Finally, Scotiabank lifted their target price on Albemarle from $70.00 to $85.00 and gave the stock a &#34;sector perform&#34; rating in a report on Monday, November 10th. One analyst  has rated the stock with a Strong Buy rating, nine have assigned  a Buy rating, eighteen have assigned  a Hold rating and two have issued  a Sell rating to the stock. According to data from MarketBeat.com, Albemarle presently has a consensus rating of &#34;Hold&#34; and an average price target of $120.21.</p><ul><li>5 Surprising Stocks Set to Benefit From a Future Robotics Boom</li></ul><p><b>Get Our Latest Stock Analysis on ALB</b></p><h2>Albemarle Stock Down 0.3%</h2><p>ALB opened at $145.47 on Tuesday. The company has a market cap of $17.12 billion, a PE ratio of -91.49 and a beta of 1.42. Albemarle Corporation has a twelve month low of $49.43 and a twelve month high of $150.72. The company has a 50-day moving average price of $114.03 and a 200 day moving average price of $89.08. The company has a quick ratio of 1.51, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. </p><ul><li>5 EV Battery and Lithium Stocks Charging the Future</li></ul><p>Albemarle (NYSE:ALB - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The specialty chemicals company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.73. Albemarle had a positive return on equity of 0.10% and a negative net margin of 0.43%.The company had revenue of $1.31 billion for the quarter, compared to analysts' expectations of $1.27 billion. During the same period in the previous year, the firm posted ($1.55) EPS. Albemarle's revenue was down 3.5% compared to the same quarter last year.  Sell-side analysts expect that  Albemarle Corporation will post -0.04 earnings per share for the current fiscal year. </p><h2>Albemarle Dividend Announcement</h2><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Friday, December 12th will be paid a $0.405 dividend. This represents a $1.62 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Friday, December 12th. Albemarle's dividend payout ratio  is currently -101.89%. </p><h2>Albemarle Profile</h2> (Free Report)<p>Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company's bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.  </p><p>Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world's foremost chemical producers.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Albemarle</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>The Last Gold Bull Market </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFMQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFMQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Albemarle Right Now?</h2><p>Before you consider Albemarle, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Albemarle wasn't on the list.</p><p>While Albemarle currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Roffman Miller Associates Inc. PA reduced its stake in Albemarle Corporation by 25.5% in Q3, selling 7,650 shares. Albemarle's stock opened at $145.47, with a market cap of $17.12 billion. Analysts have mixed ratings, with a consensus 'Hold' and an average price target of $120.21. Albemarle reported Q3 revenue of $1.31 billion, beating expectations, but earnings per share were negative. The company announced a quarterly dividend of $0.405, with a yield of 1.1%.</p>

Roffman Miller Associates Inc. PA Sells 7,650 Shares of Albemarle Corporation $ALB